
Jose M Vidal-Taboada

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/319222/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Altered expression of the immunoregulatory ligand-receptor pair CD200-CD200R1 in the brain of Parkinson's disease patients. Npj Parkinson's Disease, 2022, 8, 27.	2.5	8
2	HLA-DQB1*05:02, *05:03, and *03:01 alleles as risk factors for myasthenia gravis in a Spanish cohort. Neurological Sciences, 2022, 43, 5057-5065.	0.9	2
3	Haplotype Analysis of the First A4V-SOD1 Spanish Family: Two Separate Founders or a Single Common Founder?. Frontiers in Genetics, 2019, 10, 1109.	1.1	0
4	KATP Channel Expression and Genetic Polymorphisms Associated with Progression and Survival in Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 2018, 55, 7962-7972.	1.9	10
5	Association of the CX3CR1-V249I Variant with Neurofibrillary Pathology Progression in Late-Onset Alzheimer's Disease. Molecular Neurobiology, 2018, 55, 2340-2349.	1.9	22
6	RNA-Seq transcriptomic profiling of primary murine microglia treated with LPS or LPS + IFNγ. Scientific Reports, 2018, 8, 16096.	1.6	35
7	Myeloid C/EBPÎ ² deficiency reshapes microglial gene expression and is protective in experimental autoimmune encephalomyelitis. Journal of Neuroinflammation, 2017, 14, 54.	3.1	18
8	Astroglia-Microglia Cross Talk during Neurodegeneration in the Rat Hippocampus. BioMed Research International, 2015, 2015, 1-15.	0.9	22
9	C/EBPβ and C/EBPΘ transcription factors: Basic biology and roles in the CNS. Progress in Neurobiology, 2015, 132, 1-33.	2.8	88
10	UNC13A confers risk for sporadic ALS and influences survival in a Spanish cohort. Journal of Neurology, 2015, 262, 2285-2292.	1.8	31
11	CX3CR1 Is a Modifying Gene of Survival and Progression in Amyotrophic Lateral Sclerosis. PLoS ONE, 2014, 9, e96528.	1.1	51
12	Different MAPT haplotypes are associated with Parkinson's disease and progressive supranuclear palsy. Neurobiology of Aging, 2011, 32, 547.e11-547.e16.	1.5	32
13	Genetic variation in APOE cluster region and Alzheimer's disease risk. Neurobiology of Aging, 2011, 32, 2107.e7-2107.e17.	1.5	59
14	Polymorphisms, haplotypes and mutations in the protamine 1 and 2 genes. Journal of Developmental and Physical Disabilities, 2011, 34, 470-485.	3.6	41
15	Pathogenic cysteine mutations affect progranulin function and production of mature granulins. Journal of Neurochemistry, 2010, 112, 1305-1315.	2.1	76
16	5′-upstream variants of CRHR1 and MAPT genes associated with age at onset in progressive supranuclear palsy and cortical basal degeneration. Neurobiology of Disease, 2009, 33, 164-170.	2.1	24
17	Human Proteinpedia enables sharing of human protein data. Nature Biotechnology, 2008, 26, 164-167.	9.4	155
18	A Common Protamine 1 Promoter Polymorphism (-190 C->A) Correlates With Abnormal Sperm Morphology and Increased Protamine P1/P2 Ratio in Infertile Patients. Journal of Andrology, 2008, 29, 540-548.	2.0	52

Jose M Vidal-Taboada

#	Article	IF	CITATIONS
19	Identification of proteomic differences in asthenozoospermic sperm samples. Human Reproduction, 2008, 23, 783-791.	0.4	253
20	<i>SPG11</i> compound mutations in spastic paraparesis with thin corpus callosum. Neurology, 2008, 71, 332-336.	1.5	29
21	Marked correlations in protein expression identified by proteomic analysis of human spermatozoa. Proteomics, 2007, 7, 4264-4277.	1.3	120
22	DNA Cards: Determinants of DNA Yield and Quality in Collecting Genetic Samples for Pharmacogenetic Studies. Basic and Clinical Pharmacology and Toxicology, 2007, 101, 132-137.	1.2	32
23	Satisfaction survey with DNA cards method to collect genetic samples for pharmacogenetics studies. BMC Medical Genetics, 2006, 7, 45.	2.1	11
24	Simultaneous genotyping of CYP2C9*2, *3, and 5′Âflanking region (C-1189T) polymorphisms in a Spanish population through a new minisequencing multiplex single-base extension analysis. European Journal of Clinical Pharmacology, 2005, 61, 635-641.	0.8	15
25	Characterisation and expression analysis of the WDR9 gene, located in the Down critical region-2 of the human chromosome 21. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2002, 1577, 377-383.	2.4	14
26	Down Syndrome Critical Region Gene 2: Expression during Mouse Development and in Human Cell Lines Indicates a Function Related to Cell Proliferation. Biochemical and Biophysical Research Communications, 2000, 272, 156-163.	1.0	22
27	Detection of a New Variant of the Mitochondrial Glycerol-3-phosphate Dehydrogenase Gene in Spanish Type 2 DM Patients. Biochemical and Biophysical Research Communications, 1999, 263, 439-445.	1.0	3
28	High Resolution Physical Mapping and Identification of Transcribed Sequences in the Down Syndrome Region-2. Biochemical and Biophysical Research Communications, 1998, 243, 572-578.	1.0	9
29	Identification of Conserved Potentially Regulatory Sequences of the SRY Gene from 10 Different Species of Mammals. Biochemical and Biophysical Research Communications, 1998, 245, 370-377.	1.0	50
30	Identification and Characterization of a New Human Gene Encoding a Small Protein with High Homology to the Proline-Rich Region of the SH3BGR Gene. Biochemical and Biophysical Research Communications, 1998, 247, 302-306.	1.0	29
31	Identification and Characterization of a New Gene from Human Chromosome 21 between Markers D21S343 and D21S268 Encoding a Leucine-Rich Protein. Biochemical and Biophysical Research Communications, 1998, 250, 547-554.	1.0	10
32	Evolution of the vertebrate H1 histone class: evidence for the functional differentiation of the subtypes. Molecular Biology and Evolution, 1998, 15, 702-708.	3.5	72
33	High-Resolution Physical Map and Identification of Potentially Regulatory Sequences of the Human SH3BGR Located in the Down Syndrome Chromosomal Region. Biochemical and Biophysical Research Communications, 1997, 241, 321-326.	1.0	12
34	Cloning and analysis of the coding region of the histone H1° -encoding gene from rat PC12 cells. Gene, 1995, 166, 313-316.	1.0	5